Preclinical Peptides & The Translational Divide
Examples of laboratory and animal peptide findings, with separate discussion of any human research. “Preclinical” describes the evidence for a particular finding; it does not mean that every compound below has never been studied in people.
Cells and animal models help investigate mechanisms and safety signals. Species, disease model, formulation, route and outcome can limit translation. Model results alone do not establish an effective or safe treatment in people.
Preclinical Research Compounds Analyzed
These examples illustrate limits of model evidence. Some also have human research, which is described separately. No whole-compound certainty grade is assigned here.
BPC-157
Synthetic 15-amino-acid peptide, GEPPPGKPADDAGLV.A 2003 rat Achilles-tendon study reported improved biomechanical and functional measures; its cell experiments evaluated tendocyte responses.
These results are not evidence of tendon healing in patients. Small uncontrolled human reports exist; they do not establish clinical effectiveness or long-term safety. A trial registration alone supplies no outcome.
FDA describes peptide characterization and safety concerns. WADA names BPC-157 in S0. Neither a compounding nomination nor a registry listing is medicine approval.
Sources: BPC-157: rat Achilles tendon and tendocyte study ↗ · FDA: BPC-157 briefing, including human reports ↗ · FDA: Peptide compounding safety concerns ↗ · WADA: Applicable Prohibited List and effective year ↗
TB-500 (thymosin beta-4 fragment)
The FDA safety entry identifies the LKKTETQ fragment; full-length thymosin beta-4 is a different intervention.The cited angiogenesis study tested full-length thymosin beta-4 in cultured endothelial cells and vessel assays. It must not be represented as a TB-500 fragment study.
Results for the full-length peptide cannot establish efficacy or safety of a fragment or a vendor product. This review does not identify a completed controlled human trial of the specified fragment.
FDA reports no identified human exposure data for the fragment. WADA lists thymosin-beta-4 and derivatives such as TB-500 in S2.
Sources: Full-length thymosin beta-4: endothelial differentiation and angiogenesis ↗ · FDA: Peptide compounding safety concerns ↗ · WADA: Applicable Prohibited List and effective year ↗
MOTS-c
A 16-amino-acid mitochondrial-derived peptide associated with the 12S rRNA region.A 2015 study investigated metabolic effects in cells and mice, including high-fat-diet models.
Experimental administration in mice does not establish patient benefit. Measuring endogenous MOTS-c in people is different from testing synthetic MOTS-c as a treatment; studies of an analog also require separate interpretation.
FDA reports no identified human exposure data for administered MOTS-c. WADA lists MOTS-c in S4.4.1.
Sources: MOTS-c: metabolic homeostasis in experimental models ↗ · FDA: Peptide compounding safety concerns ↗ · WADA: Applicable Prohibited List and effective year ↗
LL-37
Human cathelicidin peptide; the clinical trial evaluated a topical formulation.Laboratory antimicrobial findings and wound-related mechanisms motivated investigation; clinical effectiveness requires patient outcomes.
LL-37 is not exclusively preclinical. A phase IIb randomized trial in 148 patients tested topical treatment for venous leg ulcers. It did not demonstrate an overall healing advantage; exploratory subgroup findings are not confirmation of general efficacy. Topical findings do not establish systemic safety.
FDA notes limited safety information and potential risks from nonclinical findings. These should not be described as proven systemic harms in humans.
Sources: LL-37: randomized venous leg ulcer trial (indexed abstract) ↗ · FDA: Peptide compounding safety concerns ↗
Why Model Findings Need Human Evaluation
Animal models can differ from patients in disease biology, exposure, immune responses and the outcomes measured. A favorable result in a model is a reason to investigate, not proof of a clinical benefit. Assess model validity, controls, replication and relevance before considering human translation.
Sources & review status
Source check:
Source check completed 10 October 2026. Independent scientific review remains pending. This is an educational selection, not an exhaustive systematic review or prescribing reference.